Linee Guida Italiane HIV 2012.pdf - SIMaST

PAZIENTE DONNA1. Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviraltherapy eras. AIDS. 2005;19:357-370.2. Collazos J, Asensi V, Cartón JA. Sex differences in the clinical, immunological and virological parameters of HIVinfected patients treated with HAART. AIDS. 2007;21:835-843.3. Squires K, Currier J, Bridge D, et al. GRACE (Gender, Race And Clinical Experience): 48-week results ofdarunavir/r-based therapy in the largest trial in North America focused on treatment-experienced women. Programand abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention;July 19-22, 2009; Cape Town, South Africa. Abstract MOPEB042.4. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-dailylopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïveHIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study. J Acquir Immune Defic Syndr.2010;53:323-332.5. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive,HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-1688.6. Patterson K, Napravnik S, Eron J, Keruly J, Moore R. Effects of age and sex on immunological and virologicalresponses to initial highly active antiretroviral therapy. HIV Med. 2007;8:406-410.7. Hodder S, Jayaweera D, Mrus J, et al. On Behalf of the Grace Study group. Efficacy and safety outcomes amongtreatment-experienced women and men treated with etravirine in gender, race and clinical experience. AIDS ResHum Retroviruses. 2012; 28(6):544-51.8. Soon G, Min, Struble K, Chan-Tack K, ET AL. Meta-Analysis of Efficacy Outcomes for Treatment-Naive andExperienced HIV-Infected Women in Randomized Controlled Clinical Trials (RCTs) (2000-2008) In: InternationalConference Antimicrobial Agents and Chemotherapy; 2010.9. Smith K, Tierney C, Daar E et al Association of race/ethnicity and sex on outcomes in ACTG A5202. In: Programand abstracts of 18th Conference on retroviruses and opportunistic infections, February 27–March 2, 2011, Boston,MA (Abstract 536).10. Hermes A, Fredrick L, Pasley M et al. Efficacy, safety and tolerability of Lopinavir/ritonavir (LPV/rtv ) in HIVinfectedwomen: Results of a Meta-analysis of 7 Prospective, Randomized clinical Trial through 48 weeks. 1 stInternational Workshop on HIV & women from adolescence through menopause. Washington DC , January 10-11,2011.11. Squires KE: Gender differences in the diagnosis and treatment of HIV. Gend Med. 2007; 4:294-307.12. Mocroft A, Gill MJ, Davidson W et al: Are there differences in starting protease inhibitors, HAART and diseaseprogression despite equal access to care? J Acquir Immune Defic Syndr. 2000;24:475-482.13. Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non-adherence: a literature review oftreatment adherence by gender from 2000 to 2011.Curr HIV/AIDS Rep. 2011;8(4):277-87.14. Clark RA. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf. 2005;28:1075-1083.15. Van Leth F, Andrews S, Grinszteijn B. 2 NN study group. The effect of baseline CD4 cell count and HIV-1 viralload on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS. 2005;19:463-471.16. De Lazzari E, Leon A, Arnaiz JA et al. Hepatoxicity of nevirapine in virologically suppressed patients accordingto gender and CD4 cell counts. HIV Med. 2008;9:221-6.17. Watts DH. Treating HIV during pregnancy : an update on safety issues. Drug Saf 2006; 29(6):467-90.18. Registro sulla tossicità dei farmaci antiretrovirali in gravidanza (safety and toxicity of antiretroviral drugs inpregnancy) disponibile presso il sito: http://www.hivatis.org).19. Hodder S, Jayaweera D, Mrus J, Ryan R, Witek J on behalf of the GRACE Study Group. 49 th Conferernce onAntimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2009. Abstract H-919.20. Currier J, Averitt Bridge D, Hagins D, et al; GRACE (Gender, Race, And Clinical Experience) Study Group. Sexbased outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-57 Currier J etal. Ann Int Med. 2010;153:349-357.